
CORD-19:12d35c12218f230c49f4dc892814ba9f1037f251 / 61291-61450
Annnotations
{"target":"https://pubannotation.org/docs/sourcedb/CORD-19/sourceid/12d35c12218f230c49f4dc892814ba9f1037f251","sourcedb":"CORD-19","sourceid":"12d35c12218f230c49f4dc892814ba9f1037f251","text":"Consequently, future clinical trials targeting T cell stimulatory receptors will undoubtedly face more stringent safety requirements by regulatory authorities.","tracks":[{"project":"CORD-19_Custom_license_subset","denotations":[{"id":"T54","span":{"begin":0,"end":159},"obj":"Sentence"}],"attributes":[{"subj":"T54","pred":"source","obj":"CORD-19_Custom_license_subset"}]},{"project":"CORD-19-Sentences","denotations":[{"id":"T53193","span":{"begin":0,"end":159},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"attributes":[{"subj":"T53193","pred":"source","obj":"CORD-19-Sentences"}]},{"project":"CORD-19-PD-UBERON","denotations":[{"id":"T86","span":{"begin":93,"end":97},"obj":"Body_part"}],"attributes":[{"id":"A86","pred":"uberon_id","subj":"T86","obj":"http://purl.obolibrary.org/obo/UBERON_0001456"},{"subj":"T86","pred":"source","obj":"CORD-19-PD-UBERON"}]}],"config":{"attribute types":[{"pred":"source","value type":"selection","values":[{"id":"CORD-19_Custom_license_subset","color":"#ec9399","default":true},{"id":"CORD-19-Sentences","color":"#93b3ec"},{"id":"CORD-19-PD-UBERON","color":"#cdec93"}]}]}}